Retatrutide is an investigational peptide medication being developed by Eli Lilly. Unlike existing weight loss treatments, Retatrutide is a triple receptor agonist, meaning it targets three key metabolic pathways:

- GLP-1 (glucagon-like peptide-1)

- GIP (glucose-dependent insulinotropic polypeptide)

- Glucagon receptors

By activating these pathways, Retatrutide aims to reduce appetite, enhance fat metabolism, and improve insulin sensitivity, offering a comprehensive approach to weight management.

Clinical trials have shown promising results for Retatrutide, including:

- Significant weight loss: Participants have experienced up to a 24% reduction in body weight over 11 months.

- Enhanced fat metabolism: Improved breakdown of fat stores.

- Preservation of lean muscle mass: Unlike some other weight loss medications, Retatrutide helps maintain muscle tissue. Dr John Burns

- Improved insulin sensitivity: Potential benefits for individuals with metabolic conditions.

These effects suggest that Retatrutide could be a powerful tool in the fight against obesity and related metabolic disorders.

Retatrutide is administered through subcutaneous injections. As it is still undergoing clinical trials, its safety profile is being closely monitored. Common side effects reported include gastrointestinal issues such as nausea, vomiting, diarrhea, and constipation. These side effects tend to be dose-dependent and may be mitigated through gradual dose escalation.

It's important to note that Retatrutide is not yet FDA-approved and is available only through clinical trials. Using unapproved versions obtained outside of clinical settings is illegal and poses significant health risks.